Tone mix
Week by week 52 weeks
Share of Kymera Therapeutics, Inc. Common Stock's 161 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 18, 2025 · tone -99Wall Street Zen Downgrades Kymera Therapeutics (NASDAQ:KYMR) to Sell-112
- Week of Sep 15, 2025 · tone +100Kymera Therapeutics (NASDAQ:KYMR) Stock Rating Upgraded by Barclays+100
- Week of Nov 10, 2025 · tone +100Kymera Therapeutics (NASDAQ:KYMR) Upgraded at Wall Street Zen+88
- Week of Aug 24, 2026 · tone +95Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $125.65+79
- Week of Jun 1, 2026 · tone +98Is Kymera Therapeutics, Inc. (KYMR) a Long-Term Biotech Winner After New Buy Rating and Coverage Launch At Canaccord?+72
- Week of Sep 14, 2026 · tone +99Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $131.62 Consensus Price Target from Analysts+69
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Kymera Therapeutics, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 7 | +57 |
| Last 30 sessions | 13 | +31 |
| Last 90 sessions | 31 | +29 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Wednesday, November 4, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletKymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High on Analyst UpgradePositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High on Analyst Upgrade | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletKymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $170.00Positive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $170.00 | www.themarketsdaily.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
3 headlines, average tone +33: 1 positive, 2 neutral and 0 negative. Showing all 3.
- www.themarketsdaily.com · 1 outletKymera Therapeutics' (KYMR) Buy Rating Reaffirmed at Truist FinancialPositive
- www.themarketsdaily.com · 1 outletKymera Therapeutics Q3 Earnings Call HighlightsNeutral
- www.tickerreport.com · 1 outletState of Wyoming Sells 4,576 Shares of Kymera Therapeutics, Inc. $KYMRNeutral
Show the table · 3 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Kymera Therapeutics' (KYMR) Buy Rating Reaffirmed at Truist Financial | www.themarketsdaily.com | 1 | Positive |
| Kymera Therapeutics Q3 Earnings Call Highlights | www.themarketsdaily.com | 1 | Neutral |
| State of Wyoming Sells 4,576 Shares of Kymera Therapeutics, Inc. $KYMR | www.tickerreport.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 30, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.fool.com · 1 outletKymera (KYMR) Q3 2026 Earnings Call TranscriptNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Kymera (KYMR) Q3 2026 Earnings Call Transcript | www.fool.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 29, 2026
1 headline, average tone +99: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletKymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer TrialPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial | www.manilatimes.net | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Kymera Therapeutics, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.